Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Browsing: Obesity & Weight Management
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
A 93-patient RCT found structured exercise after gastric bypass did not improve the primary 2-hour glucose endpoint but added modest weight and fat-mass loss. PICO summary and expert commentary.
A small randomised trial finding that weight loss reduced IL-1β and MASLD comparably with liraglutide or lifestyle, and that baseline IL-1β predicted the extent of MASLD improvement. PICO summary and expert commentary.
The NIGOHealth randomized trial found no effect of a low glycaemic index/slow digesting carbohydrate product on primary maternal glycaemia outcomes in obese pregnant women, with only a small secondary HbA1c difference. PICO summary and expert commentary.
A single-centre Chinese RCT found a mobile health lifestyle programme modestly reduced gestational weight gain and fasting glucose in overweight or obese pregnant women, with no effect on gestational diabetes incidence. PICO summary and expert commentary.
A randomised non-inferiority trial of a low-energy total diet replacement programme in people with type 2 diabetes at high eating-disorder risk: PICO summary and expert commentary.
An exploratory secondary analysis of two Phase 2 trials reports that oral orforglipron lowered blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3, and hsCRP versus placebo, though no cardiovascular events were measured. PICO summary and expert commentary.
A small single-centre randomised trial testing weight-lowering hypoglycaemic agents plus a high-protein diet and moderate exercise against standard care for diabetes remission in adults with obesity. PICO summary and expert commentary.
An exploratory randomised trial of an 880 kcal/day total diet replacement programme in 17 adults with compensated MASLD cirrhosis found safe weight loss and reduced liver fat, but cannot confirm efficacy. PICO summary and expert commentary.